Demographic features of enrolled patients at registration
| RA | Other RDs | Total | |
|---|---|---|---|
| Patients (n) | 959 | 83 | 1042 |
| Age, years (median, IQR) | 24–93 (69, 13) | 40–92 (70, 16) | 10–93 (69, 13.25) |
| Sex, female/male | 257/702 (73.2) | 27/57 (67.9) | 284/759 (72.8) |
| Disease duration, months (median, IQR) | 1–697 (98, 130) | 3–350 (43, 76) | 1–697 (93.5, 128) |
| Prednisolone | |||
| Patients (n) (%) | 373 (38.9) | 81 (97.6) | 454 (43.6) |
| Average dose, mg/day | 4.02 | 9.03 | 5.10 |
| ≥5 mg, number (%) | 186 (19.4) | 71 (85.5) | 257 (24.7) |
| Biologic DMARDs, number (%) | 274 (28.8) | ||
| Etanercept | 103 | ||
| Infliximab | 34 | ||
| Adalimumab | 33 | ||
| Tocilizumab | 48 | ||
| Abatacept | 24 | ||
| Golimumab | 29 | ||
| Others | 3 | ||
| Methotrexate | |||
| Patients (n) (%) | 751 (79.1) | 17 (18.9) | |
| Average dose, mg/week | 7.52 | ||
| Other ISDs (%) | 154 (16.2) | 32 (35.6) | |
| Tacrolimus | 122 | 10 | |
| Mizoribine | 28 | 8 | |
| Leflunomide | 6 | ||
| Azathiopurine | 10 | ||
| Others | 3 | ||
Patients with other RDs, including 24 patients with polymyalgia rheumatica, 15 with systemic lupus erythematosus, 15 with vasculitis syndrome, 7 with myositis and 22 with others.
DMARDs, disease-modifying antirheumatic drugs; ISDs, immunosuppressive drugs; RA, rheumatoid arthritis; RD, rheumatic disease.